Diagnosis and Management of Polycystic Ovary Syndrome in Adolescents

In this article, we review the etiology and pathogenesis of PCOS, and provide guidance on the clinical assessment, diagnosis, and treatment of this disorder. Polycystic ovary syndrome (PCOS) is a common female reproductive disorder that often manifests during adolescence and is associated with disruptions in health-related quality of life. Prompt evaluation and clinical support after diagnosis may prevent associated complications and optimize overall health management. This article incorporates the most recent evidence and consensus guidelines to provide an updated review of the pathogenesis, clinical presentation, diagnostic evaluation, and management strategies for adolescents with this complex condition. We will review the recent international guidelines on PCOS; because the diagnosis of PCOS remains controversial, management of this condition is inconsistent. In 2019, PCOS remains a common, yet neglected, condition, in part, because of the lack of agreement around both diagnosis and management.

[1]  X. Ruan,et al.  Why does Polycystic Ovary Syndrome (PCOS) Need Long-term Management? , 2019, Current pharmaceutical design.

[2]  L. Kimble,et al.  A mixed-methods study of coping and depression in adolescent girls with polycystic ovary syndrome , 2019, Journal of the American Association of Nurse Practitioners.

[3]  H. Randeva,et al.  Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis , 2019, Systematic Reviews.

[4]  Z. Asemi,et al.  Vitamin D and probiotic co-supplementation affects mental health, hormonal, inflammatory and oxidative stress parameters in women with polycystic ovary syndrome , 2019, Journal of Ovarian Research.

[5]  S. Atkin,et al.  Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome , 2018, Therapeutic advances in endocrinology and metabolism.

[6]  A. Dokras,et al.  Beyond fertility: polycystic ovary syndrome and long-term health. , 2018, Fertility and sterility.

[7]  N. Nader,et al.  A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome , 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[8]  L. Redman,et al.  Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome , 2018, Clinical endocrinology.

[9]  Madhu Jain,et al.  Effect of Orlistat Versus Metformin in Various Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Randomized Control Trials , 2018, The Journal of Obstetrics and Gynecology of India.

[10]  Durgesh Gupta,et al.  Comparison of Metformin and N Acetylcysteine on Clinical, Metabolic Parameter and Hormonal Profile in Women with Polycystic Ovarian Syndrome , 2018, The Journal of Obstetrics and Gynecology of India.

[11]  X. Ruan,et al.  Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance , 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[12]  K. Ong,et al.  An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence , 2017, Hormone Research in Paediatrics.

[13]  R. Fanchin,et al.  Dysregulation of the Anti‐Müllerian Hormone System by Steroids in Women With Polycystic Ovary Syndrome , 2017, The Journal of clinical endocrinology and metabolism.

[14]  J. Sanfilippo,et al.  Polycystic ovary syndrome in adolescents. , 2017, Best practice & research. Clinical obstetrics & gynaecology.

[15]  K. Djafarian,et al.  Effect of omega-3 fatty acids supplementation on insulin resistance in women with polycystic ovary syndrome: Meta-analysis of randomized controlled trials. , 2017, Diabetes & metabolic syndrome.

[16]  A. Siejka,et al.  The pathogenesis and treatment of polycystic ovary syndrome: What's new? , 2017, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[17]  F. Fang,et al.  Effect of vitamin D supplementation on polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. , 2017, Complementary therapies in clinical practice.

[18]  K. Curtis,et al.  Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. , 2017, Contraception.

[19]  M. Trent,et al.  Treatment Considerations for the Cardiometabolic Signs of Polycystic Ovary Syndrome: A Review of the Literature Since the 2013 Endocrine Society Clinical Practice Guidelines. , 2016, JAMA pediatrics.

[20]  S. Milla,et al.  Is ultrasound useful in the diagnosis of adolescents with polycystic ovary syndrome? , 2015, Journal of pediatric endocrinology & metabolism : JPEM.

[21]  B. Saleh,et al.  The role of anti-Mullerian hormone and inhibin B in the assessment of metformin therapy in women with polycystic ovarian syndrome , 2015, Saudi medical journal.

[22]  L. Gathercole,et al.  Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome , 2015, The Lancet.

[23]  B. Viollet,et al.  Metformin: from mechanisms of action to therapies. , 2014, Cell metabolism.

[24]  R. Pasquali,et al.  Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. , 2014, European journal of endocrinology.

[25]  M. Murad,et al.  Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline , 2013, The Journal of clinical endocrinology and metabolism.

[26]  Shunping Wang,et al.  Racial and Ethnic Differences in Physiology and Clinical Symptoms of Polycystic Ovary Syndrome , 2013, Seminars in Reproductive Medicine.

[27]  H. Teede,et al.  Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. , 2013, Human reproduction.

[28]  W. Kraus,et al.  Effects of exercise on lipoprotein particles in women with polycystic ovary syndrome. , 2009, Medicine and science in sports and exercise.

[29]  J. Stark,et al.  Follicle dynamics and anovulation in polycystic ovary syndrome. , 2008, Human reproduction update.

[30]  J. Marshall,et al.  Polycystic Ovary Syndrome in Adolescence , 2008, Annals of the New York Academy of Sciences.

[31]  M. Trent,et al.  Effects of polycystic ovary syndrome on health-related quality of life , 2007, Expert review of pharmacoeconomics & outcomes research.

[32]  R. Azziz,et al.  Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. , 2005, The Journal of clinical endocrinology and metabolism.

[33]  S. Vesely,et al.  Ferriman Gallwey self-scoring I: performance assessment in women with polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[34]  M. Trent,et al.  Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. , 2005, Ambulatory pediatrics : the official journal of the Ambulatory Pediatric Association.

[35]  E. Battle,et al.  Laser‐assisted hair removal for darker skin types , 2004, Dermatologic therapy.

[36]  R. Deutsch,et al.  Relationship of GnRH‐stimulated LH release to episodic LH secretion and baseline endocrine‐metabolic measures in women with polycystic ovary syndrome , 2004, Clinical endocrinology.

[37]  J. Stark,et al.  Formation and early development of follicles in the polycystic ovary , 2003, The Lancet.

[38]  M. Trent,et al.  Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. , 2003, Journal of pediatric and adolescent gynecology.

[39]  R. Legro,et al.  Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. , 1999, Molecular endocrinology.

[40]  Ahmed Zaheer,et al.  A comparison of current acne grading systems and proposal of a novel system , 1997, International journal of dermatology.

[41]  S. Franks,et al.  Polycystic ovary syndrome. , 1995, Archives of disease in childhood.

[42]  K. Segal,et al.  Evidence for Distinctive and Intrinsic Defects in Insulin Action in Polycystic Ovary Syndrome , 1992, Diabetes.

[43]  S. Jean Emans,et al.  Pediatric and adolescent gynecology , 1992 .

[44]  Dolian Gg,et al.  Diagnostic criteria for polycystic ovary syndrome , 1989 .

[45]  S. Evron,et al.  A novel use of spironolactone: treatment of hirsutism. , 1980, The Journal of clinical endocrinology and metabolism.

[46]  D. Ferriman,et al.  Clinical assessment of body hair growth in women. , 1961, The Journal of clinical endocrinology and metabolism.

[47]  T. Bednarczuk,et al.  Total testosterone to dihydrotestosterone ratio assessed by LC-MS/MS predicts a worse metabolic profile not only in PCOS patients. , 2017, Ginekologia polska.

[48]  A. Atkinson,et al.  Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate. , 2001, QJM : monthly journal of the Association of Physicians.

[49]  D. Ehrmann,et al.  Diagnosis of the polycystic ovary syndrome in adolescence: comparison of adolescent and adult hyperandrogenism. , 2000, Journal of pediatric endocrinology & metabolism : JPEM.

[50]  R. Pasquali,et al.  Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. , 1989, The Journal of clinical endocrinology and metabolism.